T1	Participants 395 426	human platelet aggregation (PA)
T2	Participants 40 66	human platelet aggregation
T3	Participants 443 515	40 aspirin-na√Øve volunteers with at least one cardiovascular risk factor
T4	Participants 613 711	20 patients with a prior diagnosis of coronary heart disease who were chronically assuming aspirin
T5	Participants 1299 1323	aspirin-treated patients
